| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 385.75% | £340,027.37 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 328.00% | £299,601.03 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 228.69% | £230,085.09 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 57.48% | £110,236.27 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 46.16% | £102,313.46 |
| Lord Mance |
|
Stryker / NYQ:SYK | 22.62% | £85,835.27 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 3.76% | £72,630.37 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -0.62% | £69,562.58 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -13.29% | £60,698.62 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -39.02% | £42,682.74 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -89.12% | £7,613.29 |